SYMBIOTEC PHARMALAB LIMITED

BSE: SYMBIOTEC544889ISIN INE899I01028

Healthcare
Pharmaceuticals
BSE IPO

Share price

₹1,245.15-7.10 (-0.57%)

as of 30 Oct 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,310.00
52W low: ₹933.80
Off 52W high: -4.95%
1M return: +5.88%
3M return: —
6M return: —
1Y return: —
20D avg volume: 77,728
50 DMA: —
200 DMA: —

Key ratios Consolidated

Market cap: ₹8,001 Cr
Current price: ₹1,245.15
52W high / low: ₹1,310.00 / ₹933.80
Face value: ₹2.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: —
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: —
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: —

Financials

Metric	Q1 FY27
Income statement
	218.15
	0.34
	218.49
	200.96
	102.96
	0.00
	46.42
	6.18
	21.82
	50.97
	17.53
	0.00
	17.53
	3.47
	14.06
	2.24
Key metrics
	45.53
	20.90%
	6.40%

Metric	Q1 FY27
Income statement
	210.84
	19.55
	230.39
	167.37
	96.12
	0.00
	35.22
	5.62
	10.15
	37.99
	63.02
	0.00
	63.02
	16.01
	47.01
	7.49
Key metrics
	78.79
	37.40%
	22.30%

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 33.27%

Quarter	September 2026	June 2026
Promoter %	33.27%	33.27%

Holder	Type	Holding	Previous	Change
Satwani Holdings LLP	Promoter	15.28%	15.28%	0.00%
Rosewood Investments	Public	14.07%	14.07%	0.00%
Anil Satwani	Promoter	11.75%	4.37%	+7.38%
Business Excellence Trust Iii - India Business Excellence Fund Iii	Public	10.24%	10.24%	0.00%
Mirae Asset Aggressive Hybrid Fund	Public	6.00%	—	—
Kashish Satwani	Promoter	4.28%	4.28%	0.00%
Valuequest Founders Conviction Lvf	Public	2.92%	2.92%	0.00%
Think India Opportunities Master Fund Lp	Public	2.76%	2.76%	0.00%
Sushil Satwani	Promoter	1.92%	1.92%	0.00%
Pi Opportunities Aif V Llp	Public	1.78%	—	—
Dymon Asia Multi-Strategy Investment (Singapore) Pte. Ltd	Public	1.58%	1.58%	0.00%
Icici Prudential Smallcap Fund	Public	1.55%	1.03%	+0.52%
Motilal Oswal Small Cap Fund	Public	1.45%	—	—
Vq Fastercap Fund Ii	Public	1.03%	—	—
Swati Sachdev	Promoter Group	0.02%	0.02%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,652	1,778.25	38.83	17.90%	+12.13% TTM	+4.79% TTM	+4.38%
Divi's Laboratories Ltd.	2,57,903	9,715.00	88.17	19.00%	+16.35% TTM	+26.84% TTM	+46.01%
Torrent Pharmaceuticals Ltd.	1,76,300	4,635.15	84.00	9.10%	+42.06% TTM	-1.92% TTM	+28.72%
Laurus Labs Limited	1,29,243	2,392.00	97.01	19.70%	+23.03% TTM	+95.38% TTM	+146.60%
Zydus Lifesciences Limited	1,24,089	1,244.00	27.02	19.20%	+21.11% TTM	-2.51% TTM	+26.13%
Dr. Reddy's Laboratories Ltd.	1,12,693	1,350.20	40.84	13.90%	-3.53% TTM	-51.90% TTM	+12.32%
Cipla Ltd.	1,11,486	1,380.00	39.07	14.90%	-0.74% TTM	-47.48% TTM	-10.42%
Mankind Pharma Limited	1,02,797	2,488.75	45.41	13.70%	+13.27% TTM	+27.60% TTM	+1.76%
Aurobindo Pharma Ltd.	96,537	1,677.80	26.02	13.60%	+9.09% TTM	+9.48% TTM	+52.18%
Lupin Ltd	91,870	2,009.00	16.55	28.40%	+28.19% TTM	+49.13% TTM	+3.29%
Glenmark Pharmaceuticals ltd	65,137	2,308.00	36.23	16.20%	+32.94% TTM	+138.48% TTM	+22.53%
Alkem Laboratories Limited	61,277	5,125.00	27.80	18.80%	+13.36% TTM	-5.52% TTM	-7.22%
Biocon Ltd.	57,365	352.00	137.76	2.90%	+9.83% TTM	-36.60% TTM	-6.63%
Abbott India Ltd. S	54,384	25,593.30	33.68	41.90%	+6.29% TTM	+11.18% TTM	-13.64%
Gland Pharma Limited	51,112	3,097.50	45.28	13.70%	+17.57% TTM	+46.55% TTM	+61.94%
Ipca Laboratories Ltd.	48,898	1,927.70	35.56	16.40%	+10.59% TTM	+67.91% TTM	+49.58%
Ajanta Pharma Ltd.	43,891	3,512.40	34.76	29.40%	+25.01% TTM	+29.70% TTM	+42.26%
GlaxoSmithkline Pharmaceuticals Ltd.	42,073	2,483.55	39.39	55.40%	+5.75% TTM	+12.41% TTM	-5.19%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Emcure Pharmaceuticals Limited	35,440	1,868.10	34.78	25.10%	+18.36% TTM	+32.39% TTM	+39.92%
Sai Life Sciences Limited	33,139	1,559.70	91.59	18.10%	—	—	+69.37%
ACUTAAS CHEMICALS LIMITED	32,770	4,002.65	74.71	27.70%	+45.18% TTM	+95.78% TTM	+134.62%
PIRAMAL PHARMA LIMITED	31,826	239.05	-152.01	0.80%	+9.43% TTM	-781.93% TTM	+18.40%
Wockhardt Ltd	30,809	1,896.10	74.42	6.40%	+18.37% TTM	+377.85% TTM	+46.86%
RUBICON RESEARCH LIMITED	26,650	1,609.90	92.46	24.30%	—	—	+164.22%
SYMBIOTEC PHARMALAB LIMITED	8,001	1,245.15	—	—	—	—	—

Filings & corporate actions

Recent announcements

Earnings Conference Call / Analysts Meet to discuss the financial performance and business updates for the quarter and half year ended September 30, 2026 (Q2FY27). The Earnings Conference ....28 Oct 2026 · Company Update / Analyst / Investor Meet
Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve To consider and approve ....28 Oct 2026 · Board Meeting / Board Meeting
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 16, 2026 for Anil Satwani, ....16 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Certificate Pursuant to regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026.5 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Symbiotec''s Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial (''DCV'') ....30 Sep 2026 · Company Update / General
Intimation of Closure of Trading Window for the second quarter of FY 2026-27.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Symbiotec Pharmalab Limited receives Establishment Inspection Report ("EIR") from U.S. FDA for its manufacturing facility in Pithampur ("SEZ") with VAI classification.29 Sep 2026 · Company Update / General
Transcript of the Earnings conference call for Analysts and Investors for Q1 Financial Year 202728 Sep 2026 · Company Update / Earnings Call Transcript
Audio Recording Of Earnings Conference Call For Analysts And Investors held today September 22, 2026.22 Sep 2026 · Company Update / Analyst / Investor Meet
Pursuant to regulation 30 and 47 of SEBI Listing Regulations, the copies of newspaper publication is attached herewith.22 Sep 2026 · Company Update / Newspaper Publication
Announcement under Regulation 30 (LODR) - Press Release21 Sep 2026 · Company Update / Press Release / Media Release
Announcement under Regulation 30 (LODR) - Investor Presentation21 Sep 2026 · Company Update / Investor Presentation
With reference to the captioned subject, this is to inform you that Board Meeting held on September 21, 2026, have inter alia consider and approved the unaudited Standalone & Consolidated ....21 Sep 2026 · Result / Financial Results
Dear Sir / Madam, With reference to the captioned subject, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, September 21, 2026, ....21 Sep 2026 · Board Meeting / Outcome of Board Meeting
Dear Sir / Madam, Pursuant to above referred Listing Regulations, we enclose herewith the details of the 'Earnings Conference Call / Analysts Meet' to discuss the financial performance ....17 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 11, 2026 for Anil Satwani, Sushil ....12 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2026 ,inter alia, to consider and approve To consider and approve ....11 Sep 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Beacon Trusteeship Ltd11 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Update on Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.3 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund2 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Closure of trading window for the quarter ended June 30, 2026.1 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.1 Sep 2026 · Company Update / General
Disclosure regarding authority to determine materiality of event or information.1 Sep 2026 · Company Update / General
Trading Members of the Exchange are hereby informed that effective from September 01, 2026, the Equity Shares of Symbiotec Pharmalab Ltd (Scrip Code: 544889) are listed and admitted to ....1 Sep 2026 · New Listing / New Listing

Board meetings

5 Nov 2026 Board Meeting - Financial Results
21 Sep 2026 Board Meeting - Financial Results